Roux-en-Y gastric bypass (RYGB) was more effective than best medical treatment in achieving albuminuria remission in patients with type 2 diabetes and obesity in an intermediate analysis of a randomized controlled trial.
“This is a new treatment paradigm to slow or arrest chronic kidney progression in patients with diabetes and obesity,” Dr. Ricardo Vitor Cohen of Oswaldo Cruz German Hospital in Sao Paulo, Brazil, told Reuters Health by email. “It can lead to practice-change.”
Coauthor Dr. Carel le Roux from University College Dublin, in Ireland, added, “This will have far-reaching implications not only to alleviate the suffering of patients or potentially preventing early death, but it will also reduce the direct healthcare cost for patients themselves or for private and public payers, because end-stage kidney disease treatment is one of the most expensive treatments any health system undertakes.”


You must be logged in to post a comment.